Advent Capital Management Supernus Pharmaceuticals, Inc. Transaction History
Advent Capital Management
- $195 Million
- Q2 2025
Shares
2 transactions
Others Institutions Holding SUPN
# of Institutions
322Shares Held
60.4MCall Options Held
18.4KPut Options Held
0-
Black Rock Inc. New York, NY10.4MShares$478 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.04MShares$278 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.81MShares$221 Million2.66% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$139 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.76MShares$127 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.46B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...